Data supporting "The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda: results of the POPVAC B randomised, controlled trial"

POPVAC B was a randomised, double-blind, placebo-controlled trial of the effect of malaria IPT with dihydroartemisinin-piperaquine (DP) on vaccine responses among schoolchildren (9-17 years) in Jinja district, Uganda (ISRCTN62041885). The aim of the trial was to comprehensively address the hypothesis that malaria infection causes suppression of responses to unrelated vaccines and that this effect can be reversed at least partially, by monthly intermittent preventive treatment (IPT) of malaria in high-transmission settings.

A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of IPT of malaria on immune response to vaccines with different characteristics.